Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Receivables (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Receivables for 16 consecutive years, with $54.6 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 15.87% to $54.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.6 million through Dec 2025, up 15.87% year-over-year, with the annual reading at $54.6 million for FY2025, 15.87% up from the prior year.
  • Receivables hit $54.6 million in Q4 2025 for Vanda Pharmaceuticals, up from $50.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $54.6 million in Q4 2025 to a low of $24.5 million in Q1 2023.
  • Historically, Receivables has averaged $37.5 million across 5 years, with a median of $35.4 million in 2023.
  • Biggest five-year swings in Receivables: surged 50.85% in 2021 and later fell 29.27% in 2022.
  • Year by year, Receivables stood at $32.5 million in 2021, then grew by 3.22% to $33.5 million in 2022, then increased by 1.92% to $34.2 million in 2023, then surged by 37.9% to $47.1 million in 2024, then grew by 15.87% to $54.6 million in 2025.
  • Business Quant data shows Receivables for VNDA at $54.6 million in Q4 2025, $50.5 million in Q3 2025, and $45.0 million in Q2 2025.